Evident Technologies announced last week that it has begun commercial production of Biotin EviFluors, its first biotinylated quantum dot fluorophores.
EviFluor offers advantages over traditional fluorophores, including brighter emission and greater stability, for applications such as cell biology, drug discovery, and cancer research, the company said. The product is available in wavelengths from blue to infrared.
De Novo Pharmaceuticals said last week that it has launched a new range of Peakexplorer screening compound libraries as a result of the company’s collaboration with Peakdale Molecular.
The libraries were designed using De Novo’s SkelGen computational drug-design platform. The first library is focused on G-protein coupled receptors and contains more than 1,000 proprietary drug-like compounds, the company said.
TSG Partners has announced the availability of market research reports on high-content screening, cell-based assays, and RNAi. Free, condensed samples of the reports can be downloaded at http://www.tsg-partners.com.
TSG Partners is a specialty corporate advisory firm focused solely on emerging and volatile sectors in the life sciences, drug discovery and development, diagnostics, environmental controls and water treatment sectors.